Evaluation of the Role of Cisplatin-conjugated-soluble Gelatin Sponge: Feasibility Study in a Swine Model
Tóm tắt
To evaluate the safety and the delivery function of cisplatin-conjugated-soluble gelatin sponge in a swine model. Fifteen healthy young swine were assigned into three groups: transarterial cisplatin infusion group, transarterial chemoembolization (TACE) with cisplatin-conjugated 120-min soluble gelatin sponge (TACE-120) group, and TACE with cisplatin-conjugated 360-min soluble gelatin sponge (TACE-360) group. A total volume of 0.8 mL/kg cisplatin in each group and 8 mg/kg soluble gelatin sponge in TACE-120 and TACE-360 groups were injected from the left hepatic artery in small increments for 10 min. Common hepatic angiography and whole-blood sampling via the left hepatic vein were conducted to explore recanalization immediately after the procedure and again at 10, 30, 60, 90, 120, 180, 240, 300, 360, and 420 min later. The area under the plasma concentration curve (AUC) of non-protein-bound platinum was compared among the three groups. Each liver was removed and cut into 10-cm-thick sections for calculating liver-damaged volume ratio. Sequential angiography depicted gradual recanalization of the occluded hepatic artery and total recanalization at 120 and 360 min after embolization in the TACE-120 and TACE-360 groups, respectively. Of the three groups, AUC0–30, AUC30–120, and AUC120–420 were significantly highest in the transarterial cisplatin infusion group (p < 0.001), the TACE-120 group (p < 0.001), and the TACE-360 group (p < 0.001), respectively. The liver-damaged volume ratio in the TACE-360 group was small (8.20 %) but significantly higher than that in the TACE-120 group (2.67 %, p = 0.014). Cisplatin-conjugated soluble gelatin sponge functions as a cisplatin carrier and is associated with tolerable liver damage.
Tài liệu tham khảo
Doyon D, Mouzon A, Jourde AM et al (1974) L’embolisation arterielle hepatique dans les tumoeurs malignes du foie. Ann Radiol 17:593–603
Goldstein HM, Wallace S, Anderson JH et al (1976) Transcatheter occlusion of abdominal tumors. Radiology 120:539–545
Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401
Katsumori T, Kasahara T (2006) The size of gelatin sponge particles: differences with preparation method. Cardiovasc Interv Radiol 29:1077–1083
Nakatsuka H (1979) Nonsurgical intraarterial gelatin sponge injection: experimental and clinical investigation of anticancer procedure. J Osaka City Med Center 28:191–223
Sato M, Yamada R (1983) Experimental and clinical studies on the hepatic artery embolization for treatment of hepatoma. Nippon Acta Radiologica 43:977–1005
Takasaka I, Kawai N, Sato M et al (2010) A new soluble gelatin sponge for transcatheter hepatic arterial embolization. Cardiovasc Interv Radiol 33:1198–1204
Kanayama Y, Aoki C, Sakai Y (2007) Development of low endotoxin gelatin for regenerative medicine. Biol Pharm Bull 30:237–241
Nishiyama N, Okazaki S, Cabral H et al (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977–8983
Ikeda Y, Tabata Y (1998) Protein release from gelatin matrices. Adv Drug Deliv Rev 31:287–301
Kanayama Y, Sakai Y, Ikoma A et al (2010) The fundamental study of sustained-release of cisplatin-absorbed gelatin. Paper presented at 40th Annual Meeting of the Japanese Society of Interventional Radiology 26:169
Ohta S, Nitta N, Sonoda A et al (2010) Embolization materials made of gelatin: comparison between gelpart and gelatin microspheres. Cardiovasc Interv Radiol 33:120–126
Ohta S, Nitta N, Sonoda A et al (2010) Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro. Br J Radiol 82:380–385
Sahara S, Kawai N, Sato M et al (2010) Prospective comparison of transcatheter arterial chemoembolization with lipiodol–epirubicin and lipiodol–cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 28:362–368
Nagata M, Matsuo Y, Hidaka M et al (2008) Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats. Biol Pharm 31:493–496
Masuda M (2002) Evaluation of basic and clinical study on effect of anticancer drugs of lipiodol in chemoembolization on liver tissue. J Wakayama Med Soc 53:185–192
Sato M, Yamada R, Uchida B et al (1993) Effects of hepatic artery embolization with lipiodol and gelatin sponge particles on normal swine liver. Cardiovasc Interv Radiol 16:348–354
Sahara S, Tanihata H, Sato M et al (2009) Effect of hepatic artery chemoembolization using cisplatin–lipiodol suspension with gelatin sponge particles on swine liver. J Vasc Interv Radiol 20:1359–1364